ASMB ASSEMBLY BIOSCIENCES, INC. Insider Trading

Gilead Sciences (10% holder) doubled Assembly stake to 4,505,391 shares, raising ownership by 103.9% via 2,295,920 share purchase.

Gilead Sciences, a 10% owner, purchased 2,295,920 shares of Assembly Biosciences on 2025-08-08, increasing its holdings from 2,209,471 to 4,505,391 shares (+103.9%). This aggressive accumulation signals material commitment to the biotech firm despite mixed prior outcomes: Gilead's two previous buys at Assembly (2024-12-19 and 2024-06-17) yielded 90-day returns of -49.2% and +19.2% respectively, suggesting limited predictive accuracy at this ticker. Assembly is unprofitable (latest quarter: -$10.2M net income) but shows explosive annual revenue growth of +298.2%, trading at $23.32—down 13.4% from its 52-week high. The doubling of position size by a strategic investor warrants examination of Assembly's pipeline progress and Gilead's strategic rationale, particularly given the company's cash-burn profile and the mismatch between Gilead's cross-ticker buy-timing success (44.44% 90-day win rate) and its poor 90-day returns at this specific ticker.

Director Houghton Michael buys 3,202 shares of ASMB at $15.61 (total $49,997.63); stock -18.8% from 52-week high, company posting -$9.6M net income.

Houghton Michael, a director at Assembly Biosciences, initiated a position of 3,202 shares at $15.61 on 2024-12-30, representing his first recorded holdings in the company. The purchase occurs while the stock trades at $15.78—just 1% above his transaction price—within the lower half of its 52-week range ($9.57–$19.43) and down 18.8% from its 52-week high. The company reported revenue of $6,845,000.00 in the latest quarter against a net loss of $9,613,000.00, with negative full-year net income, indicating ongoing operating losses. The near-exact match to the $50,000 round figure suggests a calculated position sizing, though the modest scale relative to the $100.3M market cap and the context of sustained unprofitability limit the signaling strength of this initial purchase.

Gilead Sciences (10% owner) purchases 940,499 shares of ASMB for $20.1M, raising stake to 2.21M shares; stock down 23.2% from 52-week high.

Gilead Sciences, a 10% shareholder in Assembly Biosciences, purchased 940,499 shares at $21.37 on 2024-12-19 for $20,098,463.63, increasing its holdings by 74.1% to 2.21M shares post-transaction. The timing occurs at a notable point in the stock's trajectory—it is down 23.2% from its 52-week high of $19.43, though the current price of $14.92 reflects an additional decline beyond the transaction price. At the company level, Assembly remains unprofitable with a net income of $-9,613,000.00 in the latest quarter and a market cap of only $94,835,787.12, raising questions about financial sustainability. Notably, Gilead's prior purchase of ASMB shares on 2024-06-17 achieved a 90-day return of +19.2%, consistent with the insider's cross-ticker track record which shows an average 90-day return of +483.3% on prior buys, though this substantial outperformance may not be replicable at a single-ticker level given the limited sample size.

10% owner Schornstein purchases 25,000 ASMB shares ($371,994.32) across 3 trades; prior 90-day buys showed 100% positive returns

Schornstein Alexander, a 10% owner, executed 3 separate purchases totaling 25,000 shares for $371,994.32 between November 22–25, 2024, at an average price of $14.88, increasing his stake by 3.6% to 728,113 shares. His prior open-market trades at ASMB show a strong timing pattern: four of four earlier buys at this ticker delivered positive 90-day returns, ranging from +17.3% to +1752.0%, suggesting a track record of entering ahead of subsequent price appreciation. This current filing comes as the stock trades at $15.20, down 21.8% from its 52-week high and down 10.1% over the past 30 days, positioning the purchase near depressed recent levels relative to the year's range. The company remains unprofitable (net income of $-9,613,000 on revenue of $6,845,000 in the latest quarter), introducing operational risk that tempers conviction-based readings of insider purchases.

10% owner Alexander Schornstein bought 10,000 shares of ASMB at $14.58 on 2024-10-08; 5 of 5 prior buys at this ticker showed positive 90d returns.

Schornstein, a 10% owner, purchased 10,000 shares at $14.58, expanding his holdings to 703,113 shares—a 1.4% increase in his position. His prior transaction history at Assembly Biosciences is notable: all 5 preceding buys produced positive 90-day returns, ranging from +14.1% to +1752.0%, with a 100% success rate at the 90-day mark. His cross-ticker track record shows an average 90d return of +1068.9% across 6 prior buys with a 100.00% win rate. The current price of $16.00 is -17.6% from the 52-week high and represents a +9.8% gain from the $14.58 purchase price, though the stock is unprofitable (net loss of $-11,152,000.00 in the latest quarter). The timing pattern—all 5 prior buys at ASMB were well-timed measured at 90 days—combined with the substantial cross-ticker historical accuracy, suggests this insider has demonstrated skill in identifying entry points that precede upward stock movement.

10% owner Schornstein buys 9,000 shares (9.0K) at avg $12.40 across 2 transactions; prior buys at ASMB all well-timed at 90d mark

Schornstein Alexander, a 10% owner, executed 2 separate purchases totaling 9,000 (9.0K shares) for $111,630.74 at a blended average price of $12.40 on 2024-07-03 and 2024-07-05. The current stock price of $13.85 sits 11.8% below the 52-week high of $15.70, and over his prior 4 trades at ASMB, all were well-timed at the 90-day mark, with 90d returns ranging from +1186.9% to +1752.0%. The company remains unprofitable (net income $-9.1M in the latest full fiscal year) with trailing quarterly revenue of $5.8M. This purchase extends a consistent pattern of well-timed insider accumulation at this ticker despite ongoing negative earnings, suggesting the insider retains conviction in the company's trajectory despite its early-stage commercial profile.

Gilead Sciences (10% owner) buys 179,500 ASMB shares, raising stake to 1,268,972 shares (+16.5%)

Gilead Sciences, holding 10% of Assembly Biosciences, executed an open-market purchase of 179,500 shares on 2024-06-17, expanding its position by 16.5% to 1,268,972 shares total. Assembly Biosciences is a pre-profitability company ($-9.1M net income over the most recent full fiscal year against $5.8M in latest quarterly revenue) with a market cap of $84.4M, and the stock is currently trading at $15.30, near its 52-week high of $15.51. Gilead's cross-ticker insider track record shows 5 prior open-market buys with an average 90-day return of +319.7%, though the 25% win rate on those trades indicates inconsistent execution timing. This purchase represents meaningful capital commitment by a major institutional stakeholder during a period of sequential price appreciation (90-day change: +17.9%), and the substantial increase in position size merits monitoring for what it may signal about Gilead's assessment of Assembly's clinical or commercial trajectory.